

MAPK14/p38 alpha (aa 1-360) Active Human Recombinant with His Tag

| | | | |
|---------------------------------|--|------------------|-------|
| Catalog No. | CRP003B | Quantity: | 25 µg |
| Description: | Recombinant human active p38-alpha MAPK (amino acids 1 to 360) has a MW ~40 kDa and an amino-terminal polyhistidine tag. | | |
| Concentration: | 0.1 mg/ml | | |
| Source: | Sf9 cells | | |
| Formulation: | Liquid in 50 mM Tris, pH 7.6 + 0.15 M NaCl + 0.27 M sucrose + 1 mM DTT + 0.1 mM EGTA + 0.2 mM PMSF + 1 mM benzamidine + 5 mM NaF + 10 mM beta-glycerol phosphate + 0.1 mM sodium vanadate + 0.03% Brij-35, carrier-free, sterile filtered through a 0.22 micron filter. | | |
| Purity: | Greater than 95% as determined by SDS-PAGE analysis. | | |
| Biological Activity: | ~230 units/mg. One unit of p38-alpha MAPK activity is equal to 1 nmol of phosphate transferred to recombinant ATF-2 fusion protein per minute at 30°C with a final ATP concentration of 100 µM. Recombinant human active p38-alpha MAPK has also been shown to phosphorylate Elk-1, STAT1, and MAPKAP kinase 2. Kinase activity may vary depending on the substrate and reaction conditions. The optimal concentration should be determined for each specific application. | | |
| Storage & Stability: | Centrifuge vial prior to opening. Store ≤-80°C. Liquid recombinant human active p38-alpha MAPK should be kept as a solution in order to maintain full activity. This stock solution should be apportioned into working aliquots and stored ≤-80°C. Avoid repeated freeze-thaw cycles. | | |

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

